Roberto Sanz-Requena1,2, Antonio J Revert-Ventura3, Gracián García-Martí4,5,6, Fares Salamé-Gamarra3, Alexandre Pérez-Girbés5, Enrique Mollá-Olmos7, Luis Martí-Bonmatí4,5. 1. Radiology Department, Hospital Quirónsalud Valencia, Av Blasco Ibañez 14, 46010, Valencia, Spain. roberto.sanz@quironsalud.es. 2. Grupo de Investigación Biomédica en Imagen, Hospital Universitari i Politècnic La Fe, Av Fernando Abril Martorell 106, 46026, Valencia, Spain. roberto.sanz@quironsalud.es. 3. Radiology Department, Hospital de Manises, Av Generalitat Valenciana 50, 46940, Manises, Spain. 4. Radiology Department, Hospital Quirónsalud Valencia, Av Blasco Ibañez 14, 46010, Valencia, Spain. 5. Grupo de Investigación Biomédica en Imagen, Hospital Universitari i Politècnic La Fe, Av Fernando Abril Martorell 106, 46026, Valencia, Spain. 6. CIBER-SAM, Instituto de Salud Carlos III, C Doctor Esquerdo 46, 28007, Madrid, Spain. 7. Radiology Department, Hospital La Ribera, Carretera de Corbera km 1, 46600, Alzira, Spain.
Abstract
OBJECTIVES: Vascular characteristics of tumour and peritumoral volumes of high-grade gliomas change with treatment. This work evaluates the variations of T2*-weighted perfusion parameters as overall survival (OS) predictors. METHODS: Forty-five patients with histologically confirmed high-grade astrocytoma (8 grade III and 37 grade IV) were included. All patients underwent pre- and post-treatment T2*-weighted contrast-enhanced magnetic resonance (MR) imaging. Tumour, peritumoral and control volumes were segmented. Relative variations of cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT), Ktrans-T2*, kep-T2*, ve-T2* and vp-T2* were calculated. Differences regarding tumour grade and surgical resection extension were evaluated with ANOVA tests. For each parameter, two groups were defined by non-supervised clusterisation. Survival analysis were performed on these groups. RESULTS: For the tumour region, the 90th percentile increase or stagnation of CBV was associated with shorter survival, while a decrease related to longer survival (393 ± 189 vs 594 ± 294 days; log-rank p = 0.019; Cox hazard-ratio, 2.31; 95% confidence interval [CI], 1.12-4.74). Ktrans-T2* showed similar results (414 ± 177 vs 553 ± 312 days; log-rank p = 0.037; hazard-ratio, 2.19; 95% CI, 1.03-4.65). The peritumoral area values showed no relationship with OS. CONCLUSIONS: Post-treatment variations of the highest CBV and Ktrans-T2* values in the tumour volume are predictive factors of OS in patients with high-grade gliomas. KEY POINTS: • Vascular characteristics of high-grade glioma tumour and peritumoral regions change with treatment. • Quantitative assessment of MRI perfusion provides valuable information regarding tumour aggressiveness. • Quantitative T2*-weighted perfusion parameters can help to predict overall survival. • Post-treatment variations of CBV and K trans-T2 values are predictive factors of OS. • Increased values may justify treatment intensification in these patients.
OBJECTIVES: Vascular characteristics of tumour and peritumoral volumes of high-grade gliomas change with treatment. This work evaluates the variations of T2*-weighted perfusion parameters as overall survival (OS) predictors. METHODS: Forty-five patients with histologically confirmed high-grade astrocytoma (8 grade III and 37 grade IV) were included. All patients underwent pre- and post-treatment T2*-weighted contrast-enhanced magnetic resonance (MR) imaging. Tumour, peritumoral and control volumes were segmented. Relative variations of cerebral blood flow (CBF), cerebral blood volume (CBV), mean transit time (MTT), Ktrans-T2*, kep-T2*, ve-T2* and vp-T2* were calculated. Differences regarding tumour grade and surgical resection extension were evaluated with ANOVA tests. For each parameter, two groups were defined by non-supervised clusterisation. Survival analysis were performed on these groups. RESULTS: For the tumour region, the 90th percentile increase or stagnation of CBV was associated with shorter survival, while a decrease related to longer survival (393 ± 189 vs 594 ± 294 days; log-rank p = 0.019; Cox hazard-ratio, 2.31; 95% confidence interval [CI], 1.12-4.74). Ktrans-T2* showed similar results (414 ± 177 vs 553 ± 312 days; log-rank p = 0.037; hazard-ratio, 2.19; 95% CI, 1.03-4.65). The peritumoral area values showed no relationship with OS. CONCLUSIONS:Post-treatment variations of the highest CBV and Ktrans-T2* values in the tumour volume are predictive factors of OS in patients with high-grade gliomas. KEY POINTS: • Vascular characteristics of high-grade glioma tumour and peritumoral regions change with treatment. • Quantitative assessment of MRI perfusion provides valuable information regarding tumour aggressiveness. • Quantitative T2*-weighted perfusion parameters can help to predict overall survival. • Post-treatment variations of CBV and K trans-T2 values are predictive factors of OS. • Increased values may justify treatment intensification in these patients.
Authors: Pejman Jabehdar Maralani; Elias R Melhem; Sumei Wang; Edward H Herskovits; Matthew R Voluck; Sang Joon Kim; Kim O Learned; Donald M O'Rourke; Suyash Mohan Journal: Eur Radiol Date: 2015-02-14 Impact factor: 5.315
Authors: R G Henry; D B Vigneron; N J Fischbein; P E Grant; M R Day; S M Noworolski; J M Star-Lack; L L Wald; W P Dillon; S M Chang; S J Nelson Journal: AJNR Am J Neuroradiol Date: 2000-02 Impact factor: 3.825
Authors: June L Chan; Susan W Lee; Benedick A Fraass; Daniel P Normolle; Harry S Greenberg; Larry R Junck; Stephen S Gebarski; Howard M Sandler Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Vittorio Stumpo; Lelio Guida; Jacopo Bellomo; Christiaan Hendrik Bas Van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra Journal: Cancers (Basel) Date: 2022-03-05 Impact factor: 6.639